SUMMARYWe review the apparent disparities between different reviews of the effects of mammographic screening on mortality from breast cancer and overdiagnosis. When results of each review are expressed with respect to a common population and a common baseline, all find a substantial mortality benefit and variation among estimates is minor. There are genuine disagreements about overdiagnosis, but methods that take account of lead time and underlying incidence trends yield estimates of overdiagnosis that are modest and are outweighed by the mortality benefit. There is potential for individualized screening regimens, particularly with respect to breast density. Mammographic screening prevents deaths from breast cancer and can be recommended.When expressed in terms of breast cancer mortality in women of average UK risk, screened regularly from the age of 50-69 years, the major reviews indicate a reduction in breast cancer mortality in the range of one life saved per 64-257 women screened.Offering screening on the basis of age (starting at either 40 or 50 years) is an effective strategy.There is scope for varying the surveillance regimen (including the imaging technology) based on family history or breast density.